
Pathalys Pharma Raises $150M Led by Abingworth; Forms Strategic Collaboration with Launch Therapeutics
Pathalys Pharma, a biotech company developing therapies for chronic kidney disease, has secured $150 million in new Secured Product and equity financing to support phase 3 clinical trials for its leading drug candidate.
Abingworth, a life sciences investment firm owned by global investment firm Carlyle, led the financing. As part of the deal, Pathalys will collaborate with Launch Therapeutics, a clinical development company backed by Carlyle.
Carlyle leapt into the biotech investment scene last year when it bought out Abingworth. At the time of the deal, Abingworth and Carlyle brought Launch Therapeutics into the fold.
The financing marks a significant milestone for Pathalys, which is headed by biopharma veteran Neal Fowler, the former CEO of Morrisville-based Liquidia Corp.
The company launched in March 2022 with backing from Catalys Pacific and DaVita Venture Group.
